Advances in Treatment of Bacterial Meningitis
Lancet 380:1693-1702,1623, Van de Beek, D.,et al, 2012
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Practice Guideline: Idiopathic Normal Pressure Hydrocephalus: Response to Shunting and Predictors of Response
Neurol 85:2063-2071, Halperin, J.J.,et al, 2015
Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Evidence-based Guideline: Treatment of Parenchymal Neurocysticercosis
Neurol 80:1424-1429, Baird, R.,et al, 2013
Evidence-Based Guideline Update: Vagus Nerve Stimulation for the Treatment of Epilepsy
Neurol 81:1453-1459, Morries, G.L.,et al, 2013
Utility of MRI in Spinal Arteriovenous Fistula
Neruol 79:25-30,15, Toossi, S.,et al, 2012
Adjunctive Dexamethasone in Adults with Meningococcal Meningitis
Neurol 79:1563-1569,1528, Heckenberg, S.G.B.,et al, 2012
Neurologic Outcomes and Adjunctive Steroids in HIV Patients with Severe Cerebral Toxoplasmosis
Neurol 79:1762-1766, Sonneville, R.,et al, 2012
Effect of Vaccines on Bacterial Meningitis Worldwide
Lancet 380:1703-1711,1623, McIntyre, P.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Evidence-based Guideline Update: Steroids and Antivirals for Bell Palsy
Neurol 79:2209-2213, Gronseth, G. & Paduga, R., 2012
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
How Beneficial is Surgery for Cervical Radiculopathy and Myelopathy?
BMJ 341:200-202, Fouyas,I.P., et al, 2010
Acyclovir Resistance in Herpes Simplex Encephalitis
Ann Neurol 67:830-833, Schulte,E.C., et al, 2010
High-Dose Cytarabine Plus High-Dose Methotrexate Versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial
Lancet 374:1512-1520, 1477, Ferreri,A.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Neurological Complications With Acute Sphenoid Sinusitis a Surgical Emergency?
Neurocrit Care 7:169-171, Poulopoulos,M. &Finelli,P.F., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Treatment of Neurocysticercosis: Current Status and Future Research Needs
Neurol 67:1120-1127, Nash,T.E.,et al, 2006